Display options
Cite
Mezzatesta C, Bornhauser BC. Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia. Front Cell Dev Biol. 2019;7:40doi: 10.3389/fcell.2019.00040.
Mezzatesta, C., & Bornhauser, B. C. (2019). Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia. Frontiers in cell and developmental biology, 740. https://doi.org/10.3389/fcell.2019.00040
Mezzatesta, Caterina, and Bornhauser, Beat C. "Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia." Frontiers in cell and developmental biology vol. 7 (2019): 40. doi: https://doi.org/10.3389/fcell.2019.00040
Mezzatesta C, Bornhauser BC. Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia. Front Cell Dev Biol. 2019 Mar 19;7:40. doi: 10.3389/fcell.2019.00040. eCollection 2019. PMID: 30941349; PMCID: PMC6433701.
Copy Download .nbib Format: NLM
Share it on

Front Cell Dev Biol. 2019 Mar 19;7:40. doi: 10.3389/fcell.2019.00040. eCollection 2019.

Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia.

Frontiers in cell and developmental biology

Caterina Mezzatesta, Beat C Bornhauser

Affiliations

  1. Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.

PMID: 30941349 PMCID: PMC6433701 DOI: 10.3389/fcell.2019.00040

Abstract

Escape from chemotherapy-induced apoptosis is a hallmark of drug resistance in cancer. The recent identification of alternative programmed cell death pathways opens up for possibilities to circumvent the apoptotic blockade in drug resistant cancer and eliminate malignant cells. Indeed, we have recently shown that programmed necrosis, termed necroptosis, could be triggered to induce cell death in a subgroup of primary acute lymphoblastic leukemia (ALL) including highly refractory relapsed cases. In this review we focus on molecular mechanisms that drive drug resistance in ALL of childhood and discuss the potential of necroptosis activation to eradicate resistant disease.

Keywords: apoptosis dysregulation; drug resistance; leukemia; necroptosis; necroptotic compounds

References

  1. Mol Biol Cell. 2004 Mar;15(3):1089-100 - PubMed
  2. Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6164-9 - PubMed
  3. J Immunol. 2004 Jun 1;172(11):6684-91 - PubMed
  4. Clin Cancer Res. 2004 Jun 1;10(11):3737-44 - PubMed
  5. Cancer Cell. 2004 Sep;6(3):241-9 - PubMed
  6. Nat Chem Biol. 2005 Jul;1(2):112-9 - PubMed
  7. Cancer Cell. 2006 Oct;10(4):331-42 - PubMed
  8. Nature. 2007 Apr 12;446(7137):758-64 - PubMed
  9. Mol Cancer Ther. 2007 May;6(5):1641-9 - PubMed
  10. Blood. 2007 Sep 15;110(6):2084-91 - PubMed
  11. Dev Cell. 2007 Nov;13(5):705-16 - PubMed
  12. Mol Cell. 2008 Jun 20;30(6):689-700 - PubMed
  13. J Biol Chem. 2008 Sep 5;283(36):24295-9 - PubMed
  14. Cancer Lett. 2009 Feb 18;274(2):233-42 - PubMed
  15. Science. 2008 Nov 28;322(5906):1377-80 - PubMed
  16. Nat Immunol. 2009 Apr;10(4):348-55 - PubMed
  17. J Immunol. 2009 Apr 15;182(8):4538-46 - PubMed
  18. Br J Haematol. 2010 Feb;148(3):487-90 - PubMed
  19. J Clin Invest. 2010 Apr;120(4):1310-23 - PubMed
  20. Pediatr Blood Cancer. 2010 Aug;55(2):260-6 - PubMed
  21. Blood. 2010 Oct 28;116(17):3197-207 - PubMed
  22. Exp Hematol. 2011 Apr;39(4):457-472.e3 - PubMed
  23. Science. 2011 Nov 25;334(6059):1129-33 - PubMed
  24. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5322-7 - PubMed
  25. Nature. 1990 Nov 22;348(6299):331-3 - PubMed
  26. PLoS One. 2012;7(7):e41945 - PubMed
  27. Nat Med. 2013 Mar;19(3):368-71 - PubMed
  28. Immunity. 2013 Feb 21;38(2):209-23 - PubMed
  29. Methods. 2013 Jun 1;61(2):156-64 - PubMed
  30. Lancet Oncol. 2013 May;14(6):e205-17 - PubMed
  31. Klin Padiatr. 2013 May;225 Suppl 1:S62-72 - PubMed
  32. Clin Cancer Res. 2013 Jul 15;19(14):3820-31 - PubMed
  33. Oncogene. 2014 Jun 5;33(23):3004-13 - PubMed
  34. Cell Death Dis. 2013 Sep 12;4:e802 - PubMed
  35. Cancer Lett. 2014 Mar 1;344(1):101-109 - PubMed
  36. BMC Cancer. 2013 Dec 06;13:580 - PubMed
  37. Nat Rev Mol Cell Biol. 2014 Feb;15(2):135-47 - PubMed
  38. Haematologica. 2014 Jun;99(6):1062-8 - PubMed
  39. Mol Cell. 2014 Apr 10;54(1):133-146 - PubMed
  40. Cell Rep. 2014 May 22;7(4):971-81 - PubMed
  41. Cancer Discov. 2014 Sep;4(9):1074-87 - PubMed
  42. Blood. 2014 Dec 11;124(25):3738-47 - PubMed
  43. Cell Death Dis. 2014 Oct 30;5:e1496 - PubMed
  44. Int J Oncol. 2015 Mar;46(3):963-72 - PubMed
  45. Cell Death Dis. 2015 Jan 15;6:e1590 - PubMed
  46. Cell Death Dis. 2015 Jan 15;6:e1593 - PubMed
  47. Nature. 2015 Jan 15;517(7534):311-20 - PubMed
  48. Cell Death Differ. 2015 Aug;22(8):1313-27 - PubMed
  49. Cancer Lett. 2015 Sep 28;366(1):32-43 - PubMed
  50. Leukemia. 2016 Mar;30(3):761-4 - PubMed
  51. Nat Genet. 2015 Sep;47(9):1020-1029 - PubMed
  52. J Clin Oncol. 2015 Sep 20;33(27):2938-48 - PubMed
  53. Science. 2015 Oct 16;350(6258):328-34 - PubMed
  54. Oncotarget. 2015 Nov 10;6(35):37066-82 - PubMed
  55. Oncogene. 2016 Jun 30;35(26):3399-409 - PubMed
  56. Clin Cancer Res. 2015 Nov 15;21(22):5030-6 - PubMed
  57. Leukemia. 2016 Jul;30(7):1599-603 - PubMed
  58. Cancer Cell. 2016 Feb 8;29(2):145-58 - PubMed
  59. Trends Cell Biol. 2016 Jun;26(6):445-461 - PubMed
  60. Biol Chem. 2016 Jul 1;397(7):671-8 - PubMed
  61. Cancer Lett. 2016 May 28;375(1):127-132 - PubMed
  62. Cell Res. 2016 May;26(5):517-28 - PubMed
  63. Cell Rep. 2016 Apr 12;15(2):274-87 - PubMed
  64. Sci Transl Med. 2016 May 18;8(339):339ra69 - PubMed
  65. Sci Transl Med. 2016 May 18;8(339):339ra70 - PubMed
  66. Dev Cell. 2016 May 23;37(4):337-349 - PubMed
  67. Cancer Lett. 2016 Sep 28;380(1):31-8 - PubMed
  68. Cancer Res. 2016 Aug 1;76(15):4579-91 - PubMed
  69. Oncol Lett. 2016 Jun;11(6):4123-4130 - PubMed
  70. Cancer Cell. 2016 Jul 11;30(1):75-91 - PubMed
  71. Cancer Discov. 2016 Oct;6(10):1106-1117 - PubMed
  72. Cell Death Differ. 2017 Jan;24(1):83-97 - PubMed
  73. Oncogene. 2017 Mar;36(11):1487-1502 - PubMed
  74. Mol Cell Biol. 2017 Feb 15;37(5): - PubMed
  75. Blood. 2017 Mar 16;129(11):e26-e37 - PubMed
  76. Trends Pharmacol Sci. 2017 Mar;38(3):202-225 - PubMed
  77. Nature. 2017 Feb 23;542(7642):479-483 - PubMed
  78. Nat Commun. 2017 Feb 15;8: - PubMed
  79. J Exp Med. 2017 Jun 5;214(6):1655-1662 - PubMed
  80. Nat Genet. 2017 Aug;49(8):1211-1218 - PubMed
  81. Cell Death Dis. 2017 Aug 3;8(8):e2967 - PubMed
  82. Cell. 2017 Aug 10;170(4):605-635 - PubMed
  83. Clin Exp Med. 2018 May;18(2):221-227 - PubMed
  84. Nat Rev Cancer. 2018 Feb;18(2):103-116 - PubMed
  85. Nature. 2018 Jan 25;553(7689):511-514 - PubMed
  86. J Clin Oncol. 2018 Apr 20;36(12):1240-1249 - PubMed
  87. Immunotherapy. 2018 Jul;10(9):787-796 - PubMed
  88. Cancer Discov. 2018 Dec;8(12):1566-1581 - PubMed
  89. Pathol Res Pract. 2018 Nov;214(11):1749-1757 - PubMed
  90. EMBO Mol Med. 2018 Dec;10(12): - PubMed
  91. F1000Res. 2018 Dec 3;7: - PubMed
  92. Cancer Immunol Res. 2019 Feb;7(2):183-192 - PubMed
  93. Blood. 1993 Jul 15;82(2):576-80 - PubMed

Publication Types